A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis.
In this randomized, double-blind study, the efficacy and safety of oral itraconazole (n = 28) and terbinafine (n = 27), each given for 2 weeks, was compared in patients with tinea capitis. Trichophyton violaceum was the major pathogen in both groups (82.1% and 88.9%, respectively). The final evaluation at week 12 showed a cure rate of 85.7% and 77.8%, respectively (P > 0.05). Adverse events noted were mild and did not warrant discontinuation of therapy.
Jahangir
M
M
Department of Dermatology, King Edward Medical College/Mayo Hospital, Lahore, Pakistan.dderma@paknet1.ptc.pk
Hussain
I
I
Ul Hasan
M
M
Haroon
T S
TS
D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D000077291:Terbinafine; D014006:Tinea Capitis / Q000188:drug therapy*; D014249:Trichophyton / Q000302:isolation & purification
D000935:Antifungal Agents; D009281:Naphthalenes; D017964:Itraconazole; D000077291:Terbinafine